Alnylam Reports Phase 1b Brezosiran Data Showing HTT Reductions

The company reported dose-dependent CSF mHTT reductions of 60–64% at month 3 at the highest dose, with a maximum individual reduction of 83%, and an encouraging safety profile. Alnylam plans a placebo-controlled pivotal study in 2027, pending alignment.